Trial Profile

Phase 1b/2 Study to Evaluate Antibody-Drug Conjugate Sacituzumab Govitecan in Combination With PARP Inhibitor Talazoparib in Patients With Metastatic Breast Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sacituzumab govitecan (Primary) ; Talazoparib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
Focus Adverse reactions

Most Recent Events

04 Jun 2024 Results (n=26) assessing safety and efficacy of Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
28 Mar 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2026.
28 Mar 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com